Company intelligence / Profile preview

BerGenBio ASA

Ownership: Private
Employees: ~50
Development stage: Other

Overview

BerGenBio developed first-in-class selective AXL inhibitors for aggressive cancers and severe respiratory diseases. Its lead asset, bemcentinib, showed promise in early clinical trials for NSCLC and AML but failed to demonstrate sufficient efficacy in recent phase II studies targeting STK11-mutant NSCLC. As of early 2025, the company has discontinued its key remaining study with bemcentinib and announced exploration of strategic alternatives following disappointing results.[10] The company also has antibody-based assets available for licensing or outlicensed.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules (e.g., bemcentinib)Monoclonal antibodies (e.g., tilvestamab)Antibody-drug conjugates (outlicensed technology)
Industry: Biotech

Drug pipeline

3 assets

bemcentinib

2 more assets in the full pipeline.

Partnerships

University of Texas Health Science Center at San Antonio / Mays Cancer Center [5][8]Swedish Orphan Biovitrum AB (“Sobi”) – collaboration on pacritinib combo trial [5][8]ADC Therapeutics – outlicensing of antibody technology for ADCT‑601 [7]

Beyond the preview

Go deeper on BerGenBio ASA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BerGenBio ASA.